Capital International Investors Sells Guardant Health Shares

Hedge fund decreases stake in cancer diagnostics company

Mar. 11, 2026 at 8:24am

Got story updates? Submit your updates here. ›

Capital International Investors, a major institutional investor, decreased its position in Guardant Health, Inc. (NASDAQ:GH) by selling 287,217 shares during the third quarter. The fund now owns approximately 4.7 million shares, or 3.72% of the company's stock, valued at nearly $293 million.

Why it matters

Guardant Health is a leading provider of liquid biopsy cancer diagnostics, and its stock has been volatile in recent months. The sale by Capital International Investors, one of the company's largest shareholders, could signal a shift in sentiment around the stock and the broader cancer diagnostics market.

The details

According to a recent 13F filing, Capital International Investors sold 287,217 shares of Guardant Health during the third quarter, reducing its stake in the company by 5.8%. The fund now owns 4,689,241 shares, or approximately 3.72% of Guardant Health's outstanding stock. The sale comes as Guardant Health's stock has experienced significant fluctuations, with the share price ranging from a 52-week low of $36.36 to a high of $120.74.

Capital International Investors sold the shares during the third quarter of 2026.
Guardant Health's stock price has ranged from a 52-week low of $36.36 to a high of $120.74.

The players